Bunge Limited

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +50

Zacks.com featured highlights include Archer Daniels Midland, Bunge, ProFrac, Cardinal and Centene

AI-generated analysis

📰 The article highlights five stocks featured in Zacks.com's weekly screen: Archer Daniels Midland (ADM), Bunge (BG), ProFrac Holding (ACDC), Cardinal Health (CAH), and Centene (CNC).

🌾 Earnings for Q1 2026 are described as strong, with several companies exceeding analyst expectations in the early reporting cycle.

⚠️ Market sentiment faces uncertainty due to ongoing geopolitical tensions involving the war in Iran and fluctuations in oil prices around the Strait of Hormuz.

📈 Archer Daniels Midland holds a Zacks Rank #1 (Strong Buy) and expects 2026 earnings per share to rise by 26% year-over-year.

🔄 ADM's Nutrition segment is recovering, specifically led by improved performance in its Human Nutrition division.

🚜 Bunge carries a Zacks Rank #2 (Buy) and anticipates an 8.1% increase in 2026 earnings per share due to its Viterra merger and operational efficiencies.

⛏️ ProFrac Holding, also ranked Zacks #2, specializes in premium fracking technology for energy exploration and expects long-term EPS growth of 28.4%.

🏥 Cardinal Health (Zacks Rank #2) plans to maintain momentum in 2026 through growth in its Pharmaceutical and Medical segments.

💊 Cardinal Health's revenue is driven by specialty therapeutics in oncology, rising biosimilar adoption, and expanding distribution partnerships.

🤵 Centene (Zacks Rank #3 Hold) sees revenue growth fueled by Medicare and Medicaid businesses, with a consensus 2026 EPS estimate of $3.01 representing a 44.7% increase.

📊 All five highlighted companies have surpassed earnings estimates in the majority of their last four quarters.

🧮 The investment strategy combines improving broker recommendations, upward earnings revisions, and the price/sales ratio as key metrics.

Bullish Signals
  • Archer Daniels Midland is sporting a Zacks Rank #1 (Strong Buy) and expects its 2026 earnings per share to increase 26% on a year-over-year basis.
  • ADM's earnings have surpassed the consensus mark in each of the last four quarters, with an average beat of 3.8%.
  • Bunge is executing a fundamental transformation anchored by the Viterra merger, expanding global origination, and processing scale while prioritizing synergy capture to enhance long-term returns.
  • Bunge expects its 2026 earnings per share to increase 8.1% on a year-over-year basis and has consistently beaten earnings consensus, averaging a beat of 15.9%.
  • ProFrac Holding supplies technology and solutions mainly to exploration and production companies in key basins like the Permian, Eagle Ford, Haynesville, Appalachia, the Bakken and the Rockies to support future earnings growth.
  • ProFrac's expected long-term (3-5 years) EPS growth rate is an impressive 28.4%.
  • Cardinal Health carries a Zacks Rank #2 and expects to maintain operational momentum in 2026 driven by steady performance across both its Pharmaceutical and Medical segments.
  • CAH's earnings surpassed the consensus mark in each of the last four quarters with an average beat of 9.3%.
  • Centene's revenue growth is driven by strong performance in its Medicare and Medicaid businesses, contributing to increased contract wins and expanding membership.
  • The Zacks Consensus Estimate for Centene's 2026 earnings is pegged at $3.01 per share, which indicates a 44.7% rise from the year-ago figure.
Risk Factors
  • Oil prices dropped sharply on Friday due to geopolitical instability, with Iran reopening then immediately declaring the Strait of Hormuz closed in response to a U.S. Navy blockade, introducing significant supply chain uncertainty.
  • Bunge's earnings beat is supported by its transformation tied to the Viterra merger, suggesting that past financial performance may not be sustainable without continued successful integration.
  • Centene carried a Zacks Rank #3 (Hold), indicating a more neutral or cautious investment outlook compared to Strong Buy or Buy ratings.
  • Centene's earnings beat consistency is mixed, with the company missing analyst estimates in one of its last four quarters despite beating in three.
Full Analysis
Zacks Investment Research published a stock watchlist on April 22, 2026, highlighting five companies that have received strong broker recommendations and positive earnings revisions following the start of the first-quarter 2026 earnings season. The article contextualizes these picks within a volatile market environment where geopolitical tensions involving Iran and fluctuating oil prices have created uncertainty for investors. The selected stocks were identified using a specific screen designed to find companies with improving broker consensus, upward earnings estimate revisions over the past four weeks, and favorable price-to-sales ratios. Among the five highlighted stocks, Archer Daniels Midland (ADM), Bunge Global (BG), ProFrac Holding (ACDC), Cardinal Health (CAH), and Centene (CNC) are presented as top performers based on recent data. Archer Daniels Midland holds a Zacks Rank #1 (Strong Buy) with analysts expecting 2026 earnings per share to increase by 26% year-over-year, following four consecutive quarters where the stock outperformed consensus estimates. Bunge Global, rated with a Zacks Rank #2 (Buy), is undergoing a transformation anchored by its Viterra merger and expects EPS to rise 8.1% for 2026, also having beaten estimates in each of the last four quarters by an average of 15.9%. ProFrac Holding, a specialist in fracking technology for the energy sector with operations in key basins like the Permian and Appalachia, carries a Zacks Rank #2 and is projected to grow earnings at a long-term rate of 28.4% over the next three to five years. Cardinal Health, also holding a Zacks Rank #2, is maintaining operational momentum through its Pharmaceutical and Medical segments, which include growth in retail chains and oncology-focused therapeutics; it has beaten estimates in four consecutive quarters. Centene, rated with a Zacks Rank #3 (Hold), sees revenue driven by its Medicare and Medicaid businesses, with the Zacks Consensus Estimate for 2026 earnings pegged at $3.01 per share, indicating a significant 44.7% rise from the prior year. The article concludes by directing readers to Zacks.com for a full trial of their Research Wizard tool and notes potential conflicts of interest involving affiliated entities trading in the mentioned securities.